AngioDynamics (NASDAQ: ANGO) insider plans $344K sale of equity awards

Rhea-AI Filing Summary

AngioDynamics, Inc. is the subject of a notice covering a proposed sale of 23,370 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ, with an indicated aggregate value of $344,004.06 as of the filing data.

The shares relate to equity awards, including 10,949 restricted stock shares granted on 07/17/2020 and 12,421 performance share units granted on 08/12/2021, identified as securities to be sold by the issuer’s insider.

Key Figures

Proposed shares to be sold: 23,370 shares Aggregate value: $344,004.06 CUSIP or identifier: 41332389 +3 more

6 metrics

Proposed shares to be sold 23,370 shares Common stock to be sold on NASDAQ

Aggregate value $344,004.06 Indicated value for 23,370 common shares

CUSIP or identifier 41332389 Identifier associated with the common stock entry

Restricted stock shares 10,949 shares Restricted Stock granted on 07/17/2020

Performance shares 12,421 shares Performance Shares granted on 08/12/2021

Proposed sale date 07/30/2026 Date tied to proposed NASDAQ sale

Key Terms

Restricted Stock, Performance Shares, Executive Financial Services

3 terms

Restricted Stock financial

"Common | 07/17/2020 | Restricted Stock | Issuer"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

Performance Shares financial

"Common | 08/12/2021 | Performance Shares | Issuer"

Performance shares are a type of company stock given to executives or employees that only become theirs if the company meets specific goals, like hitting certain profits or growth targets. They motivate leaders to work toward the company’s success, because their additional shares depend on achieving these results.

Executive Financial Services financial

"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/30/2026 - 06:03 PM Accepted by SEC EDGAR 07/30/2026 - 06:02 PM Learn about SEC filing dates

FAQ

What does AngioDynamics (ANGO) disclose in this Form 144 filing?

The filing covers a proposed sale of 23,370 AngioDynamics common shares through Morgan Stanley Smith Barney LLC on NASDAQ, tied to earlier restricted stock and performance share awards granted in 2020 and 2021.

How many AngioDynamics (ANGO) shares are proposed to be sold and on which market?

The notice lists a proposed sale of 23,370 common shares of AngioDynamics on the NASDAQ market, with Morgan Stanley Smith Barney LLC Executive Financial Services involved as the brokerage platform for the transaction.

What is the aggregate value of the AngioDynamics (ANGO) shares covered by this Form 144?

The shares covered have an aggregate indicated value of $344,004.06. This value corresponds to the 23,370 common shares referenced in the filing and reflects the pricing information used at the time of preparing the notice.

Which AngioDynamics (ANGO) equity awards are associated with the shares to be sold?

The proposed sale relates to 10,949 restricted stock shares granted on 07/17/2020 and 12,421 performance shares granted on 08/12/2021, each identified as securities to be sold by an issuer insider.

What dates are tied to the AngioDynamics (ANGO) shares and awards in this Form 144?

Key dates include the grant of restricted stock on 07/17/2020, grant of performance shares on 08/12/2021, and a proposed transaction date of 07/30/2026 for selling 23,370 common shares on NASDAQ.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	23370	344004.06	41332389	07/30/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/17/2020	Restricted Stock	Issuer			10949	07/17/2020	Not Applicable
Common	08/12/2021	Performance Shares	Issuer			12421	08/12/2021	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)